Get informed when a big investor buys or sells
+ FollowOvervalued by 162.1% based on the discounted cash flow analysis.
Loading insider trades…
Loading congress trades…
| Market cap | $417,883.00 |
|---|---|
| Enterprise Value | $11.74 Million |
| Earnings per Share | $-15.9 |
| Beta | 0.47 |
| Outstanding Shares | 2,767,440 |
| P/E Ratio | -0.01 |
|---|---|
| PEG | 0.01 |
| Price to Sales | - |
| Price to Book Ratio | 0.03 |
| Enterprise Value to Revenue | 8.41 |
| Enterprise Value to EBIT | -0.58 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 1.02 |
| Debt to Equity | 0.68 |
No data
Compares institutional put options with call options. At 0.00, the ratio is below 1, so institutions hold more calls than puts.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Holdings and activity of institutional investors.
| Ownership % | 0.00%▼ 0.00% |
|---|---|
| Total Invested | $256▼ 99.55% |
| Investors Holding | 2▼ 8.00% |
advanced excimer laser-based vascular and dermatological therapies we are a commercial-stage medical device company leveraging our advanced excimer laser-based platform for use in the treatment of vascular and dermatological diseases. we...